Adaptive Biotechnologies Posts Negative P/E –38.02, Price/Sales 8.21 and COO Sells 38K Shares
Adaptive Biotechnologies enters its May 5, 2026 Q1 report with negative P/E of –38.02 and EV/OCF of –54.04 despite an 8.21 price-to-sales ratio. COO Julie Rubinstein sold 19,060 shares at $14.61 and another 19,060 at $14.18, while the current ratio remains at 3.34.
1. Q1 2026 Earnings Preview
Adaptive Biotechnologies will release its first-quarter 2026 results on May 5. Investors are focused on top-line growth potential reflected in an 8.21 price-to-sales ratio even as profitability remains elusive.
2. Profitability and Cash Flow Challenges
The company reports a negative price-to-earnings ratio of –38.02 and negative earnings yield of –2.63%. Its operating cash flow is also in deficit, with an EV/OCF ratio of –54.04, underscoring ongoing losses.
3. Insider Transactions
Julie Rubinstein, President and COO, sold 19,060 shares at $14.61 on April 15 and another 19,060 at $14.18 on April 16, totaling 38,120 shares divested, drawing investor scrutiny.
4. Liquidity and Leverage Position
Adaptive Biotechnologies holds a current ratio of 3.34, indicating strong short-term liquidity, and a debt-to-equity ratio of 1.28, showing moderate use of debt financing.